BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements
BioCryst Pharmaceuticals, Inc. (BCRX) reported trailing twelve-month revenue of $940.6M (up 68.7% year on year) and net income of -$384.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $373.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCRXBioCryst Pharmaceuticals, Inc.Follow BCRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.6 | 26.3 | 17.3 | 13.6 | 48.3 | 26.4 | 25.2 | 20.7 | 48.8 | 17.8 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 940.6 | |
| Gross profit | — | — | — | 13.6 | 46.9 | 24.1 | 24.0 | — | 45.1 | 16.3 | 149.9 | 264.4 | 326.9 | 438.4 | 855.8 | — | |
| Research & development | 57.2 | 49.2 | 41.9 | 51.8 | 72.8 | 61.0 | 67.0 | 84.9 | 107.1 | 123.0 | 208.8 | 253.3 | 216.6 | 174.6 | 166.1 | 197.8 | |
| Operating income | -49.6 | -33.9 | -30.7 | -45.8 | -39.4 | -48.6 | -57.4 | -94.2 | -99.5 | -174.8 | -177.7 | -148.4 | -103.7 | -2.5 | 341.0 | -313.2 | |
| Pre-tax income | — | -32.1 | -21.5 | -27.9 | -43.0 | -55.1 | -65.8 | -101.3 | -108.9 | -182.8 | -181.8 | -244.4 | -226.2 | -87.0 | 267.4 | -381.2 | |
| Income tax | — | — | — | 17.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3 | 2.7 | 0.3 | 1.9 | 3.5 | 3.5 | |
| Net income | -56.9 | -39.1 | -30.1 | -45.2 | -43.0 | -55.1 | -65.8 | -101.3 | -108.9 | -182.8 | -184.1 | -247.1 | -226.5 | -88.9 | 263.9 | -384.7 | |
| Diluted EPS ($) | -1.26 | -0.79 | -0.55 | -0.68 | -0.59 | -0.75 | -0.78 | -0.98 | -940.00 | -1090.00 | -1030.00 | -1.33 | -1.18 | -0.43 | 1.21 | -1.44 | |
| Diluted shares (mn) | — | — | — | — | 72.9 | 73.7 | 84.5 | 103.2 | 0.1 | 0.2 | 0.2 | 185.9 | 192.2 | 206.7 | 218.6 | — |
USD millions · SEC XBRL
BioCryst Pharmaceuticals, Inc. — questions
- What is BioCryst Pharmaceuticals, Inc.'s revenue?
- $940.6M over the twelve months to 2026-06-30, up 68.7% year on year, from its 10-Q and 10-K filings.
- What is BioCryst Pharmaceuticals, Inc.'s net income?
- -$384.7M over the twelve months to 2026-06-30.
- What is BioCryst Pharmaceuticals, Inc.'s free cash flow?
- $373.4M over the twelve months to 2026-06-30.
- What are BioCryst Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.44 over the twelve months to 2026-06-30.
Every figure on this page comes from BioCryst Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.